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Background: Viral Hepatitis is regarded as a serious concern to human wellbeing, 
affecting millions of individuals yearly. The leading cause of this disease is the 
infection of Hepatitis A, B, C, D, and E. Consequently, leading to several 
complications, including liver cirrhosis and tumor formation. The World Health 
Organization (WHO) estimated that one in three people around the globe have been 
infected by either HBV or HCV. 
 Objectives: We aim to achieve the highest level of accuracy and reliability of our 
testing, and to evaluate the primary and secondary tests used to diagnose HBV and 
HCV at the medical commission of Qatar.  
Methods: This retrospective study was conducted based on recorded laboratory results 
for hepatitis B (n=1061) and hepatitis C (n=1399) during the period of January 1, 2019, 
to December 31, 2019. The obtained data for hepatitis B included ARCHITECT 
immunoassay; while the hepatitis C data included ARCHITECT immunoassay, 
INNOLIA (line immune Assay), and Polymerase chain reaction (PCR). 
Results: A total of 334.313 HBV and 334.312 HCV cases were analyzed in Medical 
commission during 2019. Data analysis was done on a total of 1061 and 1399 positive 




results showed high reproducibility and reliability of the Architect assay as indicated 
by the 100% overall percent agreement and positive percent agreements between the 
different runs of the test as well as different Architect analyzers. Regarding HCV 
results, our analysis indicated that Architect did not show a high percent agreement 
with those of PCR (overall percent agreement and PPV was 5.77%).  
Conclusion: The study illustrated that the agreement percentage was the highest for 
Ant-HBS and Anti-HCV with excellent performance for the Architect system. It 
demonstrated high specificity and 99.91% overall agreement with different Architect 
analyzers. and 100% positive predictive agreement. Yet, Architect had 67.20% overall 
agreement between HBsAg round 2 final positive and Architect neutralization test. 
Regarding HCV testing, the Architect demonstr ated high specificity with a 100% 
overall agreement between round 1 and round 2 of anti-HCV testing. Besides, it showed 
a 100% positive predictive agreement between Architect anti-HCV round 2 and PCR 
as well as Architect anti-HCV round 2 and INNO-LIA HCV. Yet, the overall agreement 
were 5.77% and 28.32%, respectively. In addition, the evaluation of INNO-LIA HCV 
and PCR showed a 100% positive predictive value with 79.22% overall agreement. The 
results showed that the procedures of the Medical commission testing platform gives 
precise and reproducible results. Therefore, there is no advantage gained from repeating 
Architect analysis, and it is recommended to healthcare facilities in Qatar to use 
Architect only one time. In this manner, we would be able to successfully save our 
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CHAPTER 1: INTRODUCTION  
Viral hepatitis is a major public health concern, affecting millions of 
individuals globally yearly. The disease, which is caused by a variety of viruses 
(A, B, C, D, E, and others), leads to several complications including liver cirrhosis 
that might end up with the formation of tumors in the infected liver. Particularly, 
the formation of hepatocellular carcinoma (HCC) leads to a high number of 
fatalities among HCV followed by HBV- infected patients (1). The two most well-
known viruses that lead to such persistent liver illness around the world are 
hepatitis B and C infection (HBV and HCV) (2). There is about three percent of 
people all over the world who have been infected with HCV; it should, however, 
be noted that the prevalence of hepatitis C virus depends on countries with 
infection rates of about 20 % in countries where the disease is endemic (3).  
Hepatitis C virus has become a model virus that determines a new model 
in virology, immunology, and science (4). The issue proceeds to trigger and 
challenge the wellbeing, due to the presence of several different complications 
that are undiscovered with different cases of HCV infections. The most common 
of these complications are liver cirrhosis and hepatocellular carcinoma (5). The 
development of HBV and its outcomes depends on many factors: genetics, other 
comorbidities, immune status of the patients, and others (6).  
There are currently several different methods in existence for the 
diagnosis of HBV and HCV. Examples include serological methods, molecular 
methods, or novel diagnostic tools. Serological methods are widely utilized as one 
of the essential ways of a testing method to ensure the presence of HCV infection 
by testing for antibody responses against Hepatitis C. A signal-to-cut-off value 




Another alternative method proposed to diagnose the HBV or HCV 
infection was molecular methods. This method was used to replace serological 
methods due to its inability of detecting active viruses especially in the early phase 
of infection(8). One of the advantages of using such a method is achieving a high 
specificity and high sensitivity as compared to serological methods and it has 
known to become as economically affordable for low-income nations with high 
prevalence rates of such infection(8). 
Also, recently, several novel diagnostic tools have been in place that 
include non-immunological Point of Care (POC) tests that utilize entire blood, 
serum, or plasma collected by venipuncture. Similarly, important advances have 
been made in the diagnostic field such as immunochromatographic strips, flow-
through tests, and tests based on solid-phase measures (9). 
All the above information reflects how vital it is to diagnose such 
infections to start treatment and decrease the burden and complications of the 
infectious disease. Serological tests to detect viral antigens or antibodies raised 
against HCV or HBV are known to be the most common tests used to diagnosis 
infections (2). Moreover, subjective and quantitative HCV atomic tests are 
utilized in cases of severe and chronic disease (8). Moreover, some novel methods 
for diagnosis can also be effectively used, such as nanoparticle-based diagnostic 
assay (10). The continuous monitoring of test accuracy and reliability in the 
Medical Commission Laboratory is required in attempting to improve the 






CHAPTER 2: STUDY OBJECTIVES 
The continuous monitoring of test accuracy and reliability in the 
Medical Commission Laboratory is required in attempting to improve the 
performance of the laboratory and enhance the laboratory quality management 
system. This study aims at determining the reliability of applied tests and identify 
the gaps in knowing the differences between the different techniques. If 
discrepancies are indicated, we will utilize acquired knowledge to improve 
protocols and eliminate inefficiencies to make the testing processes more 
consistent (reliable), repeatable, and reproducible. The ultimate goal of the study 
is to limit the spread of communicable diseases in the community, by accurately 
detecting the infections in newcomers. Besides, this study considered the first of 
its kind to use large sample size and compare between the performance between 
Architect instruments, INNOLIA and Architect, and finally between PCR and 









CHAPTER 3: LITERATURE REVIEW 
Although plague jaundice has existed since old civilization, the discovery of 
viruses as the main etiology of the disease was not known except in the last few decades 
(1). In 1989, HCV was discovered as the main cause of hepatitis (non-A and non-B). 
More liver illnesses were also found to be correlated to HCV, with the virus being the 
main cause of persistent liver diseases around the globe. 
3.1. Global burden of the disease 
The number of HBV and HCV cases are in a continuous increase (1). The most 
updated report from the World Health Organization (WHO) had shown that the number 
of people infected with HCV is around 185 million. On the other hand, 240 million 
people were reported to be infected with HBV and are always subjected to develop 
cirrhosis and hepatocellular carcinoma (HCC), which in turn might lead to their death. 
Every year there are about 780,000 people who are newly infected with HBV (11). 
Moreover, the number of mortality rate recorded due to HBV and HCV can reach up to 
1.3 million individuals annually around the world, where one in every three infected 
individual dies from the infection (1). Such fatalities are due to severe illness, chronic 
infection, cirrhosis, and HCC. Twenty percent of the disease arising from HCV 
Infection occurs in Africa specifically in the Sub-Saharan Area (SSA). In Africa, the 
numbers of HCV infections seem to be higher than those recorded in Europe and the 
USA, however, there is an essential need to have more accurate information and 






3.2. Types of hepatitis diseases 
There are five well-known viruses that cause nearly all hepatitis infections (1).  
1. Hepatitis A virus (HAV) causing HAV infection. 
2. Hepatitis B virus (HBV) causing HBV infection. 
3. Hepatitis C virus (HCV) causing HCV infection. 
4. Hepatitis D virus (HDV) causing HDV infection.  
5. Hepatitis E virus (HEV) causing HEV infection.   
3.3. HCV 
3.3.1. Prevalence (Geographical Distribution) of HCV worldwide 
It is estimated that three to four million people are infected every year, and 
350,000 individuals die yearly from HCV related causes (13). An evaluated 71 million 
individuals in the world are living with HCV, many of which stay asymptomatic at the 
early stages; however, they still require treatment (12). Figure 1 shows the global 






3.3.2. Prevalence (Geographical Distribution) of HCV regional 
African and Asian nations have the most HCV predominance, while industrialized 
nations in America, Europe, and Australia have low predominance (14). In the MENA 
region, Egypt reports the highest predominance of HCV infection, reaching 22% (3). 
According to WHO, the number of HCV infections was reported with a prevalence of 
71 Million worldwide in 2017.  The incidence was estimated as 1.75 million new HCV 
infections per year. It was reported to be 15% in the Eastern Mediterranean Region 
(15).  
3.3.3. Prevalence (Geographical Distribution) of HCV Qatar 
Qatar is characterized by a low prevalence of HCV, with a rate of 0.82% in the total 
population, and only 0.2% among Qataris (2013-2016 estimates). Tackling the issue of 
HCV in Qatar is not an easy task due to the rapid growth of the community with the 
convergence of immigrants from hepatitis high-burden countries (5). 
3.3.4. Morphology and classification  




In 2014, HCV was classified into seven significant genotypes and 67 sub-
categories. Several additional subtypes have been established worldwide, which are 1a, 
1b, 2a, 2b, 2c, 3a, 4a, 4d, 5a, and 6a. Subtypes typically differ by >15% in their genome 
sequence. Thus, HCV includes a high degree of heterogeneity through the genome (5). 
HCV belongs to the Flaviviridae family that has a single-stranded RNA genome, with 
icosahedral symmetry. Its viral spikes on the outer layer of the virion are nearly 6 nm 
in size, and they shape heterodimers of E1 And E2 Glycoproteins (3). 
3.3.5. The entry of the virus 
The virus binds to hepatocytes at first, as its host cells. Usually contributed to 
an interaction between HCV E1–E2 envelope Glycoproteins and Glycosaminoglycans 
(Chokes) as seen in (Figure 2 ) (3). Due to an affiliation of HCV with (exceptionally) 
Low-Density-Lipoproteins [(V)LDL], the LDL receptor (LDLr) has also been proposed 
as a capture molecule. (16), Figure 3 explains the virus entry (17).     
3.3.6. Translation and replication 
Viral RNA discharged into the cytoplasm is deciphered through an inner ribosome 
section location (IRES) found within the 5′ non-translated locale of the genome (Board 
2). The RNA encodes a ∼3000 amino acid long polypeptide that is split into ten 
distinctive items. Processing is done by host cell signal peptidases and two viral 
enzymes, which are cysteine protease dwelling in nonstructural protein 2 (NS2) and 
(NS3) serine protease that is actuated by communication with NS4A(16). Modes of 
Transmission It is known that HCV is transmitted through three different ways (2):  
1. Blood Transmission 
2. Vertical Transmission 







The most common route of the transmission globally was reported to be the blood 
transfusion, especially in the period before the start of blood screening in 1990. 
Furthermore, Organ transplantation, and the reuse of syringes, medical instruments, 
catheters had also been shown to be a common source of infection. Moreover, HCV  










A. Factors affecting HCV infection 
a. Host factors 
Host factors in genes related to the immune response may affect the course and 
outcome of HCV. Among those factors are different types of cytokines, chemokine, 
and interleukins that combat the virus on different levels during the infection. 
Furthermore, natural killer cells and T cells such as cytotoxic lymphocyte-associated 
Antigen 4 (CTLA4) have also been shown to participate in limiting the spread of the 
virus within the body (18). 
  






b.  Viral factors 
HCV diversity is the main viral factor that plays a role in disease development, 
control, and reaction to viral therapy. This is because it has previously been reported 
that the response to interferon therapy differs according to the HCV genotype. 
Specifically, genotype 1 and 4 infected patients showed poor response to the interferon 
therapy alone when compared with those infected with genotypes 2 or 3.  
However, the genotype 1 infected patients responded well to the combination of 
interferon and ribavirin treatment, where they reached Sustained Virologic Response 
(SVR) of 40–50%. In contrast, patients infected with genotypes 2 and 3 showed an SVR 
amount of 75%. Besides this significant effect of different genotypes, differences in the 
HCV genome and the virus load starting point, are considered two additional factors 
that play a role in the response against the virus treatment (18). Although this dramatic 
effect has been seen with different genotypes, the effect on HCV infection is minor in 
the long term, where all genotypes have been reported to show severe liver diseases. 
However, patients infected with genotype three have shown to be associated with a high 
possibility to develop liver steatosis(4).    
B. The lack of protective immunity 
It is believed that there is a role for adaptive immunity in virus protection. This 
important immune component was concluded from the fact that twenty-five percent of 
infected patients cleared the virus without treatment. The majority of those patients 
(83%) were capable of overcoming any recurring virus infection. This was seen from 






C. Risk factors for reinfection 
Several individuals are considered to be at high risk of infection with HCV which 
include drug users, males having sex with males, illegal sexual activities, and HIV 
infected patients (13). All those individuals are at high risk of re-infection with the 
virus; therefore, these individuals are subjected to mandatory screening for the virus 
before and after treatments. Screening could be done by antibody detection i.e. an 
elevated level of antibodies against HCV (19). 
D. Genetic susceptibility 
Several specific alleles had been reported to be strongly associated with HCV 
occurrence and clearance. Of these, DRB1*1101-DQA1*0501- DRB1*0401-
DQA1*03-DQB1*0301 haplotypes had been reported with the virus clearance and/or 
infection(20). For example, DQB1*0301 showed a crucial role in the self-limitation of 
HCV infection in different populations. Moreover, the IFNk4 gene was found to be 
correlated with the clearance of the virus in several cases. Such clearance depends on 
targeting specific and multiple virus epitopes by T cell responses (CD4+ and CD8+) or 
by the interferon ISG dependent expression in hepatocytes (20, 21). 
3.3.8. Diagnosis 
A. Serological methods 
Serological measures are frequently utilized as the essential line of a testing 
method for assurance of ingrained infection with HCV Disease, to rule in those who 
might be potentially infected and so advantage from the evaluation for treatment. Given 
that no one test is ever 100% sensitive or specific, a couple of uninfected individuals 
may likely be ruled-in as HCV; while several infected individuals may be ruled-out 
from HCV. Both Anti-HCV may be tested utilizing serum or plasma examples with 





All testing methods should aim at the accuracy of the test so it is as close as 
possible to 100% to minimize misdiagnosis chances. If the test determines antibodies 
to HCV in an individual, then the individual has already been subjected to HCV. Having 
said that, only 60%–80% of those individuals can be infected and HCV viremia, while 
the infection is likely to be cleared in the rest (7). 
Testing for antibody responses against hepatitis C infection (anti-HCV) is 
suggested for the initial identification of the contaminations. An S/CO is a laboratory 
comparison of some measurable feature of a specimen to the standard set by the 
laboratory's positive control. Samples with an S/Co ratio of ≥1.0 are defined as positive. 
A signal-to-cut-off value (S/CO) can be used so that no other tests are needed to be 
conducted(1). Results that fall below S/co >3.0can be found in non-infected patients 
and are considered to be false positive (1). Additionally, the utilization of quantitative 
PCR tests for HCV testing is essential for the appraisal of unremitting hepatitis ailment 
(7). The Anti-HCV test was created, to begin with, by enzyme-linked immunosorbent 
test which includes a great affectability and specificity.It has been replaced by 
automated chemiluminescent immunoassay (CLIA)  since the research facility 
computerization patterns and preferences that had enhanced affectability and 
specificity. 
In any case, in certain clinical settings, the chance of false-positive anti-HCV 
result is uncommon. This is because the larger part of people undergoing tests have 
proven of liver disease and the affectability and specificity of the screening measures 
are high.  However, among the population with a low (<10%) prevalence of HCV 
infection, false-positive results do occur. On the other hand, false-negative results do 
occur, which is particularly problematic in asymptomatic peoples with no clinical data 




Since the plausibility of false-positive results happens, especially in low-
prevalence settings such as testing of blood benefactors. On the other hand, positive 
anti-HCV EIAs are usually confirmed with extra tests such as Recombinant 
Immunoblot Measures (RIBA) and strip immunoblot measures (SIA such as INNO 
LIA).  
These tests utilize the same proteins as EIA tests of the same period, but the 
antigens are customarily autonomously localized to choose the number and character 
of antigens to which anti-HCV antibodies are facilitated. Further, the clinical practice 
after distinguishing a positive Anti-HCV EIA test is the degree of HCV RNA to assess 
whether viremia is displayed (22). The fourth-generation anti-HCV Enzyme-linked 
Immunosorbent assay (ELISA) detects HCV capsid antigen and antibodies to the core, 
NS3, NS4, and NS5 regions of the virus(23). The HCV core antigen test can be utilized 
in resource-limited settings. It is a profoundly precise immunoassay that can decrease 
the high rates of checking. HCVcAg measures may, moreover, be valuable as a one-
step screening test in a high predominance population.  
Any case could be a two-step Chemiluminescent Microparticle Immunoassay 
(CMIA) (Modeler HCV Ag), which appeared high affectability and specificity of 
HCVcAg (24). The serologic demonstrative tests begin by utilizing the steps for 
recognizing the infection, without distinguishing between acute and chronic infection. 
Examinations for patients with HCV disease incorporate serological measures for 
antibodies to Hepatitis C (hostile to- HCV) and atomic tests for the location of Viral 





B. Molecular methods 
One of the major problems in the diagnosis using serological methods is the lack 
of detection of the active virus during the early phases of infection or viremia before 
the formation of detectable levels of antibodies(8). The molecular diagnostic methods 
appear to resolve this problem with higher specificity and more sensitivity as compared 
to the serological ones. Because of their importance in diagnosis, those assays become 
currently available at affordable and economical prices that can accommodate the 
economy of poor nations that have a high prevalence of the virus. One of those methods 
is the Nucleic Acid Test (NAT), which is considered to be the most advanced, more 
reliable, highly accurate, very specific, and sensitive among all techniques(8). 
NAT is used as a principal test to detect the genome of different viruses in the 
sample. Also, it can be used as a confirmatory test for the positive serological test. 
Hence, this is a test that can be applied for the diagnosis of HCV in patient samples as 
primary detection as well as confirmation for the presence of the viral RNA. The NAT 
procedure is standard among all known methods that start with viral nucleic acid 
purification and followed by its amplification in a thermal cycler.  
A crucial point in this method is the correct choice of the primers that specifically 
bind to the conserved regions present in the virus genome. In the case of Viral RNAs 
like HCV, a step of reverse transcription is added to generate cDNA for PCR 
amplification. One of the known NAT available is the Cobas Taq Screen MPX test that 
has been used in the detection of different viral genomes such as HCV (RNA) and HBV 
(DNA) (25). NAT could be qualitative or quantitative, the qualitative method is known 
as conventional PCR or RT-PCR (Real-Time PCR), where the results are either 
showing that samples are reactive or non-reactive, whereas the Quantitative method 
accurately reflects the amount of the virus genome. Quantitative (q) RT-PCR detects 




specificity and sensitivity that reaches 99%(23). Indeed, Albertoni et al. (2014) were 
able to detect HCV RNA as low as 310 IU/ml using qRT-PCR(25).  
Molecular methods used to detect HCV ranges from subjective HCV test to deep 
analysis of the genome. A subjective test is used to identify circulating HCV in the 
blood, which is considered an important initial step in HCV diagnosis that screen for 
infected persons. Moreover, the detection of viral RNA is crucial for the diagnosis of 
infected individuals, carriers, seroconverted cases, and to differentiate active from 
dormant cases.  
The advantage of molecular methods is not limited to screening only but also 
extends to genotyping. This method helps to distinguish between different genotypes 
as there are about seven virus genotypes and more than eighty HCV subtypes. Besides 
NAT, hybridization and sequencing methods could be used for a more deep analysis of 
the virus genotype(8). 
In case NAT is not available, because of the limitation in resources, other 
economically affordable methods, ELISA and CLA, could be used to detect HCV core 
antigens. Importantly, it has been found that the detection of HCV core antigen is a very 
effective diagnostic method as compared to NAT. Based on this, the new Architect 
HCV Ag Test was developed by Abbot company to be one of the sensitive methods to 
detect HCV in patient samples (23). 
3.4  HBV 
3.4.1  Prevalence (Geographical Distribution) HBV Worldwide 
Depending on the WHO report, around two billion individuals are infected with 
HBV around the world, and about 600,000 people die annually due to its acute or 
chronic consequences. In other words, roughly one-third of the World's population has 





Figure 4: Figure 4 Prevalence of HBV worldwide. 
 
 
3.4.2 Prevalence (Geographical Distribution) HBV regional  
Among the globe, SSA is considered to have a high level of HBV infection within 
its population, where about 6.1% of Africans caught the virus and developed the 
disease. Similarly, in the southern and eastern parts of Asia, HBV infection was 
reported in about 100 million cases. On the other part of the globe, in the Caribbean 
and Latin American countries, the percentage of HBV infected individuals reached 
~1% of the population. Those countries had also shown a high number of HCV infected 
patients (7-9 million) in association with HBV. Moreover, in the Middle East region, 
HBV cases were reported in about 3.3% of the population. In contrast to those regions 
in the world, North America showed the lowest HBV prevalence(1). Regarding WHO 





3.4.3 Prevalence (Geographical Distribution) HBV Qatar 
In Qatar, the prevalence of HBV is less than 2%, putting into consideration that 
the population in Qatar is a very heterogeneous population, where the highest 
percentage of the individuals are expatriates coming from different parts of the globe. 
The highest numbers are from Asia that is being recorded as one of the highest numbers 
of HBV infections(5). 
 3.4.4 Morphology and classification  
HBV may be a part of the Hepadnaviridae family where HBV genotypes 
contrast by more than 8%. Additionally, eight genotypes of HBV, called A, B, C, D, E, 
F, G, and H, can be recognized whereby, these sub genotypes vary by at least 4%. In 
genotypes A, B, and C, epidemiological information appears that the individual sub 
genotype sets A1/A2 (once named Aa/Ae), B1/B2 (once in the past Bj/Ba) and C1/C2 
(once Cs/Ce) contrast significantly in numerous virologic and likely a few clinical 
parameters. All HBV genotypes can be isolated into sub genotypes but E and G.  (Figure 

















    
 Figure   Genotypes of HBV 
Figure 5: Appears the genotypes of HBV  




3.4.5 The entry of the virus 
The entry begins with reversible and non-cell-type explicit relationship to cell-
associated heparan sulfate proteoglycans, then specific and possibly irreparable binding 
to associate unknown hepatocyte-specific preS1-receptor. This step presumptively 
needs activation of the virus, thus leading to the presentation of the myristoylated N-
terminus of the L-protein. In this case, two diverse section pathways are proposed: 
endocytosis taken after by unharness of nucleocapsids from endocytic vesicles; and a 
combination of the infective operator envelope at the cell divider (27). 
3.4.6 Translation and replication 
One of the important steps in the virus life cycle is the replication phase. This 
starts with the presence of the viral nucleocapsid in the nucleus, which is followed by 
the delivery of the rcDNA into the nucleoplasm. Then this is followed by a ligation 
process of the two DNA strands which is considered a crucial step for the formation of 
cccDNA. This special piece of DNA consists of non-histone as well as histone proteins 
and it is a critical molecule synthesized by the virus to use the cell on different levels 
of transcription and translation to synthesize the Viral RNAs and produce viral proteins 
that are important for both replication and assembly (27). Figure 6 shows the 
Replication cycle of HBV (28).  
3.4.7 Modes of Transmission 
HBV transition routes include percutaneous (i.e., puncture through the skin) or 
mucosal (i.e., direct contact with mucous membranes) exposure to infectious blood or 






A. Factors affecting HBV infection 
a. Host factors 
Several host elements had been detailed to be included in virus replication. Some 
of these factors help in transcription, whereas others play a role in translation. For 
example, the CCAAT/enhancer-binding protein (C/EBP) and hepatocyte nuclear 
factors (HNF) are cellular transcription factors that mediate transcription as well as viral 
gene expression. The virus recruits those proteins to interact with the promoters display 
in its open perusing outlines (ORFs) (four overlapping ones) to produce different virus 
structural and non-structural proteins, like the nucleocapsid, precure protein, the 
envelope proteins (M, L, and S)(27). 
b. Viral factors 
Viral proteins (center, the administrative X-protein) control the method of 
translation and may change viral quality expression by collaboration with the viral 
promoters of the four major (ORFs). Viral variables can control the cccDNA 
arrangement. As HBV polymerase inhibitors do not specifically influence the cccDNA, 
a diminish in cccDNA levels is assumed to infer from the need of adequate reusing of 
viral nucleocapsids to the core, due to the restraint of viral DNA-synthesis within the 
cytoplasm, and less approaching infections from the blood(27).  
c. Environmental factors 
Natural components are involved in HBV pathogenesis. Liquor and aflatoxin 
were found to influence the movement of persistent Hepatitis B. Liquor utilization 
increases the seriousness of the liver infection and raises the chances of creating liver 
decompensation from cirrhosis. Patients with unremitting Hepatitis B presentation to 
aflatoxins are at an elevated risk of HCC(30, 31). Change of living conditions might 





B. The lack of protective immunity 
HBV infection could result in either acute (more than 90% of the cases) or 
chronic illness. HBV infections are among the top ten causes of death worldwide 
(Hunt,2007). Both antibodies and cytotoxic T cells coordinated to diverse HBV 
antigens play a vital part in diminishing viral load while clearing HBV-Infected 
hepatocytes from the liver. Unlike grown-ups who generally do not develop the 
persistent disease, neonates, and newborn children who acquire HBV disease from their 
moms at birth, are most vulnerable to the foundation of persistent HBV disease. Having 
a safe reaction plays a fundamental role in HBV-related hepatocyte destruction since 
the virus itself is not cytolytic (11). 
C. Risk factors for reinfection 
HBV reactivations and reinfections are usually associated with 
immunosuppression, such as that found in HIV infection. Also, relatively low Anti-Hbs 
levels and discontinuation of Truvada (tenofovir disoproxil fumarate and emtricitabine) 
can cause re-infection (33). 
D. Genetic susceptibility 
As described by Zhang et al. (2019), HLA-DPA1 rs3077 and HLA-DPB1 
rs9277535 are correlated with chronic HBV infection. HLA-DPA1*0202-DPB1*0501 
and HLA-DPA1*0202-DPB1*0301 are also associated with susceptibility to chronic 
hepatitis B whereas HLA-DPA1*0103-DPB1*0402 and HLA-DPA1*0103-
DPB1*0401 can have a protective effect. Also, associations between genes encoding 
cytokines (including IL-1, IL-4, IL-6, IL-10/IL-10RB, IL-12/IL-12B, IL-18, IL-27, IL-






A. Serological methods 
The essential conclusion of HBV diseases is made by utilizing serological tests 
for identifying antigens and antibodies against this infection. Hepatitis B infection 
(HBV), maybe a somewhat double-stranded DNA infection, a species of the class 
Orthohepadnavirus, and a part of the Hepadnaviridae family of infections.  
HBV infection is typically detected by immunoassays that use HBV to capture 
antigens in the sample. As with most of the serological assays, nonspecific binding can 
occur. Manufacturers determine a cutoff value that balances the necessary high 
sensitivity for detecting the antigen (or Anti-HBsAg antibody) while avoiding false-
positive results (2). HBsAg, Anti-HBs, HBeAg, Anti -HBe, Anti -HBc IgM, and IgG 
are all serological markers that can be used in the diagnosis of HBV. HBsAg and Anti 
-HBs can be detected in patients with HBsAg positive and they are regarded as carriers 
of HBV (34). 
The Hepatitis B surface antigen (HBsAg) is the main serologic diagnostic tool 
of HBV infection and is a very sensitive and specific biomarker. Chemiluminescence 
(CLIA) and electrochemiluminescence technology (ECLIA) are now used for 
extremely sensitive immunoassays on automated analyzers for HBV serology. 
However, since HBsAg assays are highly sensitive, false positives can occur, 
and therefore, when HBsAg index values are close to the cut off value and are 
inconsistent with other serological markers, then another confirmatory assay is 
recommended. Standard enzyme-linked immunoassay (ELISA) can be used for 
diagnosis as it is not expensive and does not require much instrumentation; it has high 
sensitivity (>99%) and acceptable specificity (>95%) for HBsAg (35). 
HBeAg is used to detect the exact phase of the disease and its seroconversion 




and mortality provided HBV DNA is low. HBcrAg or Hepatitis B core‐related antigen 
consists of antibodies that can detect three proteins, HBcAg, HBeAg, and p22cr which 
is a small core‐related protein found in DNA‐free empty particles. HBcrAg can be used 
as a marker for intrahepatic replication, especially in cases with HBeAg seroconversion 
(36). 
The HBsAg ELISA Kit was used for the diagnosis of HBV. As described by the 
researchers, the HBsAg Antigen covers the titer wells of the plate. Then HBsAb 
antibodies in serum or plasma are added to the wells together with an HBsAg 
conjugated with peroxidase. After that Antigen-Antibody–Antigen complex 
represented by the HBsAg conjugated to peroxidase are formed. HBcAb ELISA Kit 
microtiter wells are covered with HBV antigens. Specimens containing Anti-HBcAg 
Antibodies (HBcAb) and Anti-HBcAg (HBcAb) will bind to the limited number of 
solid-phase sites(37). 
Anti‐HBc or Hepatitis Core Antibody can detect both past HBV infection and 
existing HBV infection. Titers of Anti‐HBc can predict therapeutic response and also a 
lack of need for HBV vaccination (Jackson et al.,2018). HBcrAg or Hepatitis B core 
related antigen can also be used as a marker for HBV. It quantifies HBcAg, HBeAg, 
and core related protein p22 (p22cr) in one test. Some studies also have postulated that 
it can be used as a potential biomarker in both HBeAg positive and negative phases of 
the infection (35). 
B. Molecular methods 
The development of Hybridization and Polymerase chain reaction (PCR) assays 
for direct determination of HBV-DNA is a product of advances in molecular biology 
techniques. The diagnosis of HBV infection can also be made by the detection of HBV 




and of HBV DNA by Southern hybridization, in-situ hybridization, or PCR(38). HBV 
DNA can detect the replication activity of the virus and is considered a reliable marker. 
This can include Signal Amplification, Target Amplification as well as Real-Time PCR 
which has come to be the standard method to detect and quantify HBV DNA in clinical 
settings (34). 
HBV DNA can show that actively replicating viruses within the hepatocytes is 
produced. It also helps in determining the stage of the disease and in monitoring the 
effect of NA therapy(36). Durgadevi et al. (2012) used a combination of serological 
and molecular methods to diagnose HBV, through serum and dried blood spots. 
Complete serological tests were performed and also PCR was performed on serum 
samples and dried blood spots. They concluded that using dried blood spots in detecting 
HBV DNA can be used as a convenient method of testing in resource-limited settings, 
as the results are comparable to serum tests(39). 
  There are several sensitive real-time PCR assays available for quantification 
of HBV DNA in plasma or serum. Examples include the Roche COBAS TaqMan HBV 
Test, Abbott RealTime HBV Assay, Siemens VERSANT HBV DNA, and Qiagen artus 
HBV RG PCR(35). Kurdi et al. (2014) mentioned the COBAS diagnosis test for HBV 
DNA quantification in human plasma and serum, which is a nucleic acid amplification 
test. This test consists of first of specimen preparation to isolate HBV DNA then 
performing PCR amplification of target DNA and at the same time deception of cleaved 
dual labeled Oligonucleotide detection probe specific to the target. Their study 
concluded the superiority of the PCR method over ELISA as it was more sensitive and 
reliable than the ELISA technique. They recommended the use of PCR methods as an 





3.5 Medical commission 
The Medical Commission of the Ministry of Public Health works effectively 
towards the implementation of a strategy consisting of the importance of functions. The 
Medical Commission is screen for residents and all travelers to the country who are 
then tested to ensure that they do not carry diseases and therefore, help the society be 
limited the spread. In Qatar, the Medical Commission department screened around 
607,601 individuals in 2019, with an estimated average of 2470 visitors per day. The 
department is mainly responsible for screening newcomers and residents for the 
following purposes: 
• Health screening is done for obtaining residence permits as well as medical 
fitness certificates while applying for a job or continuing university study. 
• Annual Health screening is done to obtain a health certificate for people who 
are working as food handlers, barbers or beauticians, as well as obtaining a 
QCHP license and changing one’s employer. 
The Medical Commission is mainly composed of the medical section, radiological 
section, and laboratory section. 
3.5.1 Laboratory section in Medical Commission:  
It conducts laboratory examinations daily as routine work by serological diagnosis 
mentioned below: 
3.5.1.1 ARCHITECT Immunoassay: 
 It is utilized for the qualitative detection of antibodies to presumed structure 
and non-structure proteins (NS3 and NS4) of the HCV as well as the detection of 
hepatitis B surface antigen (HBsAg) of HBV in human serum and plasma In addition 





Architect immunoassay I Abbott types: 
1-The ARCHITECT i2000SR immunoassay analyser 
• It has maximum throughput of up to 200 tests per hour 
• It features a load-up capacity of 135 samples with 35 priority and 100 
routine areas 
• It consists of 25 refrigerated reagent positions 
2-The ARCHITECT i4000SR immunoassay analyzer 
• It offers a maximum throughput of up to 400 tests per hour 
• It Features a load-up capacity of 285 samples with 35 priority and 250 
routine areas 











3.5.1.2 INNO-LIA HCV Line Immune Assay (LIA): 
 The INNO-LIA can be uses to detect HCV and HIV viruses; For HCV score is 
a Line Immune Assay (LIA) that is used to help detect the presence of antibodies to 
HCV in human serum or plasma. The goal of this test is to be used as a supplementary 
test on human serum or plasma specimens (Figure 8) (41).  That usually found to be 
reactive using an anti-HCV screening procedure. Besides, it is also considered as a 
third-generation line immunoassay which helps incorporates HCV antigens derived 
from the core region, the E2 hypervariable region (HVR), NS3 helicase region, NS4A, 












Figure 9: INNO-LIA HCV Score test strip. The intensity of the reaction on the control 
lines on each strip is used to assign the reactivity ratings for each antigen on that strip. 
If the intensity of antigen line reaction (R) is: 1) Lower than ±, then the rating is 
negative 2) Equal to ± then the rating is ± 3) Higher than ±, but lower or equal to 1+ 
then the rating is 1+ 4) Higher than 1+ but lower than 3+ then the rating is 2+ 5) 







3.6 Routine of work 
 
ARCHITECT is a chemiluminescent microparticle immunoassay (CMIA) that 
is often used for detection several viruses most frequently the ARCHITECT is used for 
HCV, HBV, and HIV antibody/antigen detection with slight differences in the 
procedures. For instance, the ARCHITECT Anti-HCV antibody is regarded as a two-
step immunoassay, whereas Anti-HBsAg qualitative II is a one-step immunoassay. The 
latter makes use of the technology of chemiluminescent microparticle immunoassay for 
the qualitative detection of Anti-HCV and Anti-HBS. 
Regarding  anti-HCV testing, the sample will be added to a microparticle coated 
with a recombinant HCV antigen. If the sample has an anti-HCV it will bind to the 
antigen coated in the microplate. Consequently, creating a reaction mixture when Anti-
human IgG/IgM acridinium-labeled conjugate is added after washing. Moreover, the 
reaction mixture also requires the addition of trigger and pre-trigger after another wash 
cycle. In this case, Relative light units (RLUs) are usually used in measuring the 
reaction resulting in chemiluminescent (43). The specimen is considered non-reactive 
(NR) if cutoff (S/CO )  values < 1.00.  In addition, reset in duplicate results is where 
the criterion of ARCHITECT Anti-HCV used when the reactive specimen is considered 
repeatedly responsive for Anti-HCV in case of one or both results being reactive. 
However, for Anti-HCV, the sample examined is considered non-reactive if both results 
are nonreactive (Figure 10). Further investigation is required in repeatedly reactive for 
Anti-HCV specimens in supplemental tests like INNOLIA assays, other HCV specific 
immunoassays, or a combination of PCR test. The specificity of ARCHITECT anti-
HCV is 99.60% with a 95% confidence interval while the sensitivity is 99.10% with a 
95% confidence interval. There is no detection limit of ARCHITECT anti-HCV 




For HBsAg qualitative II testing, similar procudeure as in anti-HCV will be 
followed except that the microplate is coated with anti-HBs. The creation of a reaction 
mixture requires the sample of Anti-HBs acridinium -labeled conjugate and Anti-HBs 
paramagnetic microparticles (44).  The specimen which is considered Retest in 
duplicate (Reactive) are those with S/CO values <OR = 1.00.  In Duplicate Reset 
Results for HBsAg, the specimens are considered nonreactive if both results were 
nonreactive. The specimen is considered repeatedly reactive if both are reactive (Figure 
11). This can then be confirmed by a neutralizing assay if reactive. The specificity 
HBsAg qualitative Confirmatory II is > 99.5% with a 95% confidence interval while 
the sensitivity is 99.09%, with a 95% confidence interval. In terms of Detection limit, 
HBsAg assay commercially available was 0.021 IU/ML as per package while adding 
the upper limit of the 95% confidential interval. For the analytical sensitivity results, 
linear regression ranging from 0.017 to 0.022 IU/ML was used in calculating the 
ARCHITECT HBsAg Qualitative II assay.  
3.7 Description neutralization test. 
 A Chemiluminescent Microparticle Immunoassay (CMIA) is the HBsAg 
Qualitative 11 confirmatory assay in human plasma and serum for the presence of 
Hepatitis B surface antigen confirmation (45).  
3.7.1 Biological Principles of the Procedure 
Both one-step pretreatment immunoassay in two single tests is involved in the 
ARCHITECT HBsAg Confirmatory V.1 assay utilizing Chemiluminescent 
Microparticle Immunoassay (CMIA) technology with Chemiflex. In a reaction vessel 
(RV), Pretreatment 1 and sample are combined and incubated. In Pre-treatment 1, the 
antibody is used to neutralize HBsAg. Creating a reaction mixture requires the 
combination of Anti-HBs coated conjugate and paramagnetic microparticles and the 




neutralized HBsAg in the sample. Thus, anti-HBs coated microparticles binding with 
the neutralized HBsAg, is blocked.  
The second steps require the addition of acridinium labeled Anti-HBs 
conjugate. The reaction mixture also involves the addition of trigger and pre-trigger 
solutions following another wash cycle. Relative light units (RLUs) are used in 
measuring the reaction resulting in chemiluminescent. The RLUs detected, and the 
ARCHITECT, which identifies the amount of HBsAg system optics, has a direct link.  
3.7.2 Interpretation results 
Using the ratio of the samples Relative light unit (RLU), the HBsAg quantitative II 
Confirmatory assay cutoff (S/CO) results are calculated by the ARCHITECT I system 
to the cutoff RLU (S/CO). The ARCHITECT I system calculates the % nutralization 
results for HbsAg quantitative II Confirmatory assay using the HBSAgQ2 and 
HBSAgQ2 C2 results. 
▪ In all cases of dilution If % Neutralization is not applicable, the final interpretation 
is not confirmed. 
▪ In all cases of dilution, If % Neutralization > or = 50%, the final interpretation is 
confirmed positive. 
▪ In case of neat dilution, If % Neutralization < 50%, the final interpretation is 
Repeat test used in a 1:500 dilution. 
▪ In case of 1:500 dilution If % Neutralization < 50 %, the final interpretation is Go 
to 1:20000 dilution. 







3.8 Description of HCV quantitative test (The COBAS AmpliPrep/COBAS) 
Taqman HCV Quantitative Test, version 2.0)  
 PCR was used for detection HCV and HIV viruses, in our cases these tests offer 
the ability to qualitatively detect hepatitis C virus or quantitatively determine amounts 
of HCV circulating in a patient’s blood. The diagnosis of acute and chronic HCV 
infection is based on the detection of HCV RNA by a sensitive molecular method. The 
qualitative test confirms HCV antibody-positive specimens and provides evidence of 
an active infection. The COBAS® AmpliPrep/COBAS® TaqMan® HCV Qualitative 
Test, v2.0 is a qualitative in vitro nucleic acid amplification test for the detection of 
Hepatitis C Virus (HCV) RNA genotypes 1 to 6 in human EDTA plasma or serum. It 
utilizes automated specimen preparation by a generic silica-based capture technique. It 
is based on three major processes: (1) specimen preparation to isolate HCV RNA; (2) 
reverse transcription of the target RNA to generate complementary DNA (cDNA) and 
(3) simultaneous PCR amplification of target cDNA and detection of cleaved dual-
labeled oligonucleotide detection probes specific to the target. 
3.9 Description of INNOLIA Biological Principles of the procedure  
INNOLIA is used to detect different viruses such as HCV and HIV. For HCV, 
the antigens are pre-coated on nylon strip and a sample is then incubated in a trough 
along with the test strip. HCV antibodies, if present, will bind to the HCV antigen lines 
on the strip. Thereafter, it is proceeded by addition of conjugate to react with specific 
HCV antigen/antibody complexes, if previously produced. Afterward, incubation with 
the enzyme substrate forms a chesnut-like color, whose intensity is proportionate to the 
amount of HCV-specific antibody taken from the sample on any given line. Color 





3.9.1 Interpretation of the results: 
A sample is negative for HCV antibodies in the following two cases:  
▪ If all HCV antigen lines experience a negative reactivity rating. 
▪ If only one HCV antigen line has a reactivity of ±, except when the reactivity is 
observed for NS3.  
On the other hand, a sample is positive for HCV antibodies if at least two HCV 
antigen lines have a reactivity of ± minimum or higher. Besides, a sample is considered 
indeterminate for HCV antibodies if one HCV antigen line has a reactivity rating of 1+ 
or higher and if the NS3 line reacts with a reactivity of ± or higher and all other antigen 


















Figure 10: HCV Architect Chart 
✓ If ARCHITECT Anti-HCV Round 2 is positive, INNO-LIA HCV is positive, 
and PCR is positive → HCV result is confirmed positive  
✓ If ARCHITECT Anti-HCV Round 2 is positive, INNO-LIA HCV is negative, 
and PCR is negative → HCV result is confirmed negative 
✓ If ARCHITECT Anti-HCV Round 2 is positive, INNO-LIA HCV is negative, 
and PCR is positive → HCV result is confirmed positive 
✓ If ARCHITECT Anti-HCV Round 2 is positive, INNO-LIA HCV is positive, 
and PCR is negative → HCV result is confirmed indetermined; → Repeat 
after 4 weeks ARCHITECT Anti-HCV Round 3, INNO-LIA HCV, and PCR 




















































































































































CHAPTER 4: METHODOLOGY  
4.1. Ethical considerations This study granted IRB exemption by the ethics 
committee of MOPH IRB and Qatar University before the study data collection. 
4.2. Inclusion and Exclusion Criteria and number of samples 
All initial reactive/positive for Anti-HCV and HBsAg blood samples that were 
collected between January 1st, 2019, and December 31st, 2019 were included and 
analyzed. 
4.3. Recruitment Methods 
No patients/applicants were involved or in other words, there was no direct or 
indirect interaction with human subjects. The study will be conducted on existing de-
identified testing results in the MC database 
4.4. Confidentiality 
The study was conducted on de-identified data. The results of testing as figures 
and only data that is non-identifiable will be published. The data was saved in the 
medical commission's password-protected database medic system, and the students had 
limited access from the section head for de-identified test results information. All 
samples were barcoded, and all sample results were stored in the medic system database 
which was password-protected to protect applicants' identities. 
4.5.  Data collection and statistical analysis 
This Retrospective study was conducted on 1120 hepatitis B (HBsAg) lab 
results from January 2019 to December 2019, which were tested positive for hepatitis 
B (HBsAg) using an Architect from Abbott (USA), and thus, included in this study. 
The replicate ARCHITECT reading was analyzed and was used for repeatability and 
reproducibility purposes.  
 




The HBsAg confirmed test results by HBsAg neutralization test of these 1120 
samples were also included and analyzed for Positive Predictive Value (PPV), true 
positive and false-positive results. For HCV testing, 1399 Anti-HCV positive samples 
during the period of January 2019 to December 2019 were included in this study. The 
replicate ELISA reading was analyzed and used for repeatability and reproducibility 
purposes. Anti-HCV confirmed results by HCV INNO LIA, and HCV PCR was also 
included and analyzed for PPV, true positive, and false-positive results. The date was 
extracted from the Medic system (Health Information System "HIS"/ Laboratory 
Information System "LIS") database using an SQL (i.e., Structured Query Language) 
script in a tool used to execute SQL scripts namely called Toad. Then the output of the 
SQL script was saved in a CSV (i.e., Comma Separated Values) text file, and then the 
CSV text file was opened in Excel and was saved as an Excel file. Then we converted 
the data into the coding system. 
4.7. Sample size calculations 
The sample size was calculated based on the confidence level using the Stephen 
Thompson equation (equation 1), which is one of the best equations for calculating the 





▪ N: Population size. 
▪ z: Standard value of the significant level (95%) and it equals 1.96 
▪ d: Error ratio and it equals 0.05 
▪ p: The ratio of the availability of the property and the neutral and equals 0.50 
The data (HCV) was collected from the Medic system program and was saved 




on an Excel file. The data was a horizontal form placed in the form of rows so that each 
row represents a case of the reviewers. Then an excel sheet was used, and the data were 
coded and classified based on the person reading. If it was greater than or equal to one, 
then the result was considered positive, and if it was less than one, then it was 
considered as negative. =IF(D12>=1;"POS";"NEG") and coding POS = 1, NEG= 0. 
 
4.8  Calculation of the different diagnostic measurements 
Equation 2: Calculation of the different diagnostic measurements (OPA, PPA, NPA, 
and PPV). 
 
▪ Overall Percent Agreement= (A+D)/(A+B+C+D) 
▪ Positive Percent Agreement = A/(A+C) 
▪ Negative Percent Agreement = D/(B+D) 







CHAPTER 5: RESULTS 
5.1 Evaluation of the performance agreement in different HCV diagnostic 
methods  
We analyzed data collected from a total of 1399 individuals who were 
previously screened for HCV during their application for Qatari residency in Doha in 
the period from January 1, 2019, to December 31, 2019. The screening process was 
previously done at the Qatar Medical Health Commission laboratory using the 
ARCHITECT immunoassay on two rounds using two different analyzers ie. analyzer 
A (round 1) and analyzer B (round 2). It is important to note that round 2 was performed 
by another technician to ensure reproducibility. The results obtained from those two 
rounds were further confirmed by NNO-LIA HCV and PCR analyses (PCR was done 
at Hamad Medical Corporation).  
Our data analysis showed that all 1399 samples screened in the ARCHITECT 
analyzer A (round 1) were HCV positive. However, in round 2 the number of samples 
analyzed was only 1393 because this round was based on recollecting blood samples 
from all positive cases. During this process, six subjects did not come back for the blood 
withdrawal.  In this case, according to the protocol, text messages are usually sent 3 
times. If the applicant still does not respond, a verification is usually carried out inside 
the Ministry of Interior system to ensure that the individual is inside or outside the 
country. If the individual is outside the country, the file is closed. As for whether he/she 
is inside the country, a communication with the responsible authorities is carried out 
within the country to inform them that the person is unfit because the preventative 
checks are incomplete. Therefore, those six samples were excluded from all our 
subsequent analyses. Consistent with the results obtained from round 1 screening using 
ARCHITECT analyzer A, all 1393 recollected samples analyzed in round 2 of the 




zero value was placed as shown in the table. 
 Indeed a 100% agreement (overall and positive percent agreements; 95% CI, 
99.72-100%) between the results obtained from the two screening rounds was observed 
(Table 5). To further confirm these results, we analyzed the data obtained from the two 
other confirmatory diagnostic tests, INNO-LIA HCV and PCR. Using the INNO-LIA 
assay, we were able to identify 311 as HCV positive, 787 HCV negative and 295 
indeterminate (HCV-specific IgG antibodies may or may not be present) (Table 2). We 
then used these results to investigate the overall percent agreement (95% CI) with the 
results obtained in round 2 using ARCHITECT analyzer B. Surprisingly, the overall 
percent agreement was 28.32% (25.73%-31.065), whereas the positive percent 
agreement (95% CI; 98.78%-100%) was 100% (Table 5).  
To ensure these results and indicate the true positive cases, we calculated the 
positive predictive value (PPV).  Similar to the results obtained for the overall percent 
agreement of the ARCHITECT analyzer B and INNO-LIA, the PPV was 28.32% 
(25.73%-31.06%) (Table 5). On the other hand, the PCR analysis showed 80 HCV 
positives and 1307 negatives (Table 3) with overall percent agreement % (95% CI) of 
5.77% (4.66%-7.12%) and positive percent agreement % (95% CI) of 100% (95.42%-
100%). Importantly, the PPV of this analysis was 5.77% (4.66%-7.12%) (Table 5). 
As a final confirmation of our diagnostic analysis, we compared the PCR and 
INNOLIA results. Of 1097 samples, 78 HCV positives, 791 negatives, and 288 
indeterminate were detected in both assays. However, 228 samples showed positive 
results in INNOLIA but were negative in PCR (Table 4). The overall percent agreement 
and positive percent agreement (95% CI) between both assays were 79.22% (76.72%-
81.52%) and 25.49% (20.93%-30.66%), respectively. Notably, the positive predictive 
















ARCHITECT anti-HCV round 2 
Positive Negative 
ARCHITECT anti-HCV round 1 
Positive 1393 0 
Negative 0 0 
INNO-LIA HCV 
Positive Negative Indetermined 
ARCHITECT anti-HCV round 2 
Positive 311 787 295 
Negative 0 0 0 
PCR 
Positive Negative 
ARCHITECT anti-HCV round 2 
Positive 80 1307 
Negative 0 0 
Table 1:Comparison between ARCHITECT anti-HCV round 1 and round 2 
Table 2: Comparison between ARCHITECT anti-HCV round 2 and INNO-LIA 
HCV 
 

























































































Order of reference standard  
INNO-LIA HCV > PCR > ARCHITECT Anti-HCV Round 2 > ARCHITECT Anti-
HCV Round 1 
INNO-LIA HCV 
Positive Negative Indetermined 
PCR 
Positive 78 0 2 
Negative 228 791 288 





5.2 Evaluation of the performance agreement in different HBV diagnostic 
methods  
For HBV data analysis, we used a similar strategy as HCV. The data was 
obtained from 1061 HBV samples that were subjected to three successive rounds of 
screening named round 1, rerun 1, and rerun 2, respectively. These runs were done on 
the same ARCHITECT analyzer (A) and by the same technician. All samples were 
HBV positive in round 1 of screening, whereas in rerun 1, 1051 samples were positive 
and 10 were HBV negative (Table 6). Comparing those two rounds, the percent 
agreement analysis showed an overall percent agreement of 99.06% (95%CI; 99.64-
100%) and a positive percent agreement of 100% (95%CI; 99.64-100%) (Table 10). On 
the other hand, the comparison between round 1 and rerun 2 showed 1060 HBV positive 
samples and only one negative sample (Table 7) with a 99.91% agreement (overall and 
positive percent agreements; 95% CI, 100% (99.64%-100%) (Table 10). Based on these 
results, HBV positive patients were recalled again for blood collection and another run 
was performed on another ARCHITECT analyzer (B) by an alternative technician 
(round 2). Consistent with the results obtained in round 1 and rerun 2 (Table 7), round 
2 of HBV screening showed 1060 positive samples and one negative sample with 100% 
agreement (Table 8 and Table 10). 
 To further confirm these results, the recollected samples from round 2 were 
subjected to another diagnostic test, HBsAg confirmatory test (neutralization test). In 
this analysis, both assays showed 712 HBV positive samples and one negative sample 
for HBV. However, there was a discrepancy in 384 samples that were positive in round 
2 but negative in the HBsAg confirmatory test (Table 9). This yielded an overall percent 
agreement of 67.20% (64.32%-69.96%). Finally, the positive percent agreement of 
















ARCHITECT HBsAg round 1, rerun 1 
Positive Negative 
ARCHITECT HBsAg round 1 
Positive 1051 10 
Negative 0 0 
ARCHITECT HBsAg round 1, rerun 2 
Positive Negative 
ARCHITECT HBsAg round 1 
Positive 1060 1 
Negative 0 0 
Table 6:Comparison between ARCHITECT HBsAg round 1, rerun 1 and round 1 











ARCHITECT HBsAg round 1 
Positive Negative 
ARCHITECT HBsAg round 2 
Positive 1060 1 
Negative 0 0 
ARCHITECT HBsAg confirmatory 
Positive Negative 
ARCHITECT HBsAg round 2 final positive 
Positive 712 348 
Negative 0 1 
Table 9: Comparison between ARCHITECT HBsAg confirmatory and 
round 2 
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CHAPTER 6: DISCUSSION  
In Medical Health Commission, the reliability, sensitivity, and reproducibility of 
HCV and HBV diagnostic assays are of significant importance. This is because the 
results obtained from these assays determine the fate of the examined individual (46). 
In Qatar, individuals tested positive for HCV or HBV are not allowed to stay in the 
country and thus their job offer usually gets withdrawn by their employer. HCV 
diagnostic scheme starts by detecting viral antibodies using different immunoassays 
and then followed by viral RNA detection to confirm positive cases using RT-PCR 
(23). Thus, the initial anti-HCV antibodies screening using those immunoassays is 
considered a crucial step in HCV diagnosis. Among those assays, ELISA based assays 
stand out as the most common method used in different labs around the world to 
primarily detect HCV infection (47, 48).  
However, false-positive results with low titer samples in HCV screening is 
considered a fundamental and common problem in many labs. Indeed, the false HCV 
positive cases range between 15%-60%, with an average of 35% among populations 
where HCV prevalence is less than 10% (48-50). Therefore, in this study, we aimed to 
assess the reproducibility and efficiency of our diagnostic HCV protocol in the Qatar 
Medical Health Commission laboratory. We did several comparisons between different 
Architect instruments as well as between different confirmatory diagnostic methods. 
Our results showed a 100% agreement in the results obtained from two different 
Architect instruments and performed by two different technicians as presented by 
overall percent agreement and positive percent agreement of 100% (Table 5). These 
results indicated the reliability and high reproducibility of our initial screening method 
using an Architect. This indicates that the Medical Commission’s testing platform 




Also, The Medical Commission’s protocol implemented in the pre-analytical 
phase regarding the applicant’s identification is a perfect one. Our data is supported by 
other reports that confirmed the diagnostic reliability of Architect in HCV diagnosis. 
These studies also affirm the high specificity and sensitivity of this assay that reaches 
up to 100% (51-54). Moreover, our results strongly agree with a large study conducted 
by Jonas et al 2005, who used ARCHITECT immunoassay analyzer from different 
centers in Germany, Sweden, and Switzerland and confirmed the high specificity, 
sensitivity, and reliability of the assay in HCV detection (55).  
Interestingly, Architect results did not show a high percent agreement with those 
of PCR (overall percent agreement and PPV is 5.77%) indicating that 5.77% of all 
Architect anti-HCV positive samples have current HCV infection. This discrepancy 
could be due to the inability of PCR assay to detect the viral RNA during the transient 
control phase of viral replication by the immune system. Furthermore, in nonviremic 
patients, no HCV RNA is detected using PCR, whereas anti-HCV antibodies could be 
easily detected by Architect in sera samples collected from those patients (56, 57). This 
could indicate that these patients might resolved HCV infection. In this case, the 
individual has to be called again for PCR detection after two weeks. Therefore, an HCV 
Ag assay would be an optimal solution to be used as the first confirmatory test 
preceding the PCR step (58, 59). This would be a more reliable, cost-effective, specific, 
and sensitive first confirmatory test as compared to PCR. Similar to the results obtained 
for the overall percent agreement of the ARCHITECT Round 2 and INNO-LIA, the 
PPV was 28.32%. This indicates 28.3% of all Architect anti-HCV positive samples 
have confirmed HCV antibodies which indicates that these 28.3% either having current, 





The overall percent agreement and positive percent agreement (95% CI) between 
both assays were 79.22% (76.72%-81.52%) and 25.49% (20.93%-30.66%), 
respectively. This indicates that 25.5% of all confirmed HCV antibody test (INNOLIA 
HCV), having current HCV infection while 74.5% having past resolved infection. Also, 
the table shows that the Negative Percent Agreement is 100% (791/791) indicating that 
all Architect ELISA HCV positive samples which were not confirmed by antibody 
HCV confirmatory test were HCV PCR negative (i.e.  not having HCV infection). Also 
the table shows 2 out of 290 INNO LIA HCV indeterminate samples having current 
HCV infection (HCV PCR Positive). An indeterminate HCV antibody confirmatory 
test indicates that the individual might be in the seroconversion period, delayed 
appearance of full specific antibodies, or nonspecific reaction. Such individual needs to 
be tested in 4 weeks to determine the definitive HCV antibody status. These two 
positive PCR results might indicate either these two individuals in the seroconversion 
period or there is delayed appearance of full specific antibodies. 
Our HBV results also showed the high reproducibility and reliability of the 
Architect assay as indicated by the 100% overall percent agreement and positive 
percent agreements between the different runs of the test as well as different Architect 
analyzers (Tables 7 and 8). Our data is in a strong agreement with another study that 
compared the results obtained from three different analyzers (Abbott Architect i2000 
Assay, the Roche Modular Analytics E170 Assay, and an Immunoradiometric Assay) 
to detect HBV antibodies and showed that the Architect i2000 showed the highest 
agreement of 97.3% (60). Yet, the overall percent agreement of 67.20% (64.32%-
69.96%) indicating that 67 % of all Architect HBsAg test positive samples have current 
HBV infection. Also, 33% (348/1060) are unconfirmed by HBsAg confirmatory test. 




conjunction with test results of other HBV serological markers such as Hepatitis B core 
antibody “total and IgM” and hepatitis B surface antibody before considering the initial 
screening test is a false positive. Repeat testing is recommended at a later date along 
with HBV DNA PCR, if clinically indicated. 
6.1 Limitations of the study 
Similar to any other study, our study had one main limitation. In this study, time 
was too limited to analyze the enormous amount of data collected during the research 
period. Therefore, we were not able to confirm the negative or non-reactive cases. 
Hence, we were not able to calculate the sensitivity and specificity due to the absence 
of the negative data. 
6.2 Future Implications 
Future studies can be done to confirm the negative or non-reactive cases while 
having enough time to analyze the data. Moreover, since our data showed that there 
was no advantage gained from repeating Architect analysis. We would recommend to 
healthcare facilities in Qatar to use Architect only one time. In this manner, we would 
be able to successfully save our limited resources, while reducing cost and time for 







CHAPTER 7: CONCLUSION  
In conclusion, Architect HBV and HCV can detect all positive cases, so if the 
case is identified as negative by the test, then it is negative. However, if the case was 
identified as positive by Architect HBV, then there is a 32.7% chance that this is false, 
and it is negative. On the other hand, if the case identified as positive by Architect HCV, 
then there is a 77.6% chance that this is false, and it is negative. Based on these 
conclusions, it is recommended to use Architect one time, if it is negative then there is 
no need for further testing. If it is positive then in almost three-quarters of the cases, it 
will be negative, hence, PCR can be done for confirmation. If PCR is positive, then 
there is no need for more tests and the case can be identified as positive. If it is negative 
in a third of cases, the case will be positive and INNOLIA can be done in this case to 
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